Arcutis Biotherapeutics (ARQT) Capital Expenditures (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Capital Expenditures of $158000.0 for Q1 2026, down 74.01% year-over-year from $608000.0 in Q1 2025, and up 102.56% quarter-over-quarter from $78000.0 in Q2 2025.
Powered by 
Analysis
Arcutis Biotherapeutics (ARQT) Capital Expenditures (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $158000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 74.01% year-over-year to $158000.0; the TTM figure through Mar 2026 stood at $236000.0 (down 68.58% YoY), while the FY2025 annual figure was $686000.0, up 379.72% from the prior year.
- Capital Expenditures for Q1 2026 stood at $158000.0, up from $78000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $608000.0 in Q1 2025, with the low at $6000.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $102500.0 (2022), against an average of $145666.7.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 95.62% in 2022, then surged 966.67% in 2023.
- Arcutis Biotherapeutics' Capital Expenditures stood at $123000.0 in 2022, then slumped by 95.12% to $6000.0 in 2023, then surged by 2283.33% to $143000.0 in 2024, then sank by 45.45% to $78000.0 in 2025, then soared by 102.56% to $158000.0 in 2026.
- Business Quant data shows ARQT's Capital Expenditures at $158000.0 in Q1 2026, $78000.0 in Q2 2025, and $608000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Arcutis Biotherapeutics | 3.12 Bn | 2.88 Bn | 118.92 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 158,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 608,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Sep 30, 2023 | 64,000.00 |
| Jun 30, 2023 | 276,000.00 |
| Mar 31, 2023 | 82,000.00 |
| Dec 31, 2022 | 123,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 80,000.00 |
| Mar 31, 2022 | 124,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Sep 30, 2021 | 137,000.00 |
| Jun 30, 2021 | 43,000.00 |
| Mar 31, 2021 | 554,000.00 |
| Dec 31, 2020 | 153,000.00 |
| Sep 30, 2020 | 110,000.00 |
| Jun 30, 2020 | 17,000.00 |
| Mar 31, 2020 | 41,000.00 |